PT  - JOURNAL ARTICLE
AU  - Wojciech Trzepizur
AU  - Maria Carmen Martinez
AU  - Pascaline Priou
AU  - Ramaroson Andriantsitohaina
AU  - Frédéric Gagnadoux
TI  - Microparticles and vascular dysfunction in obstructive sleep apnoea
AID  - 10.1183/09031936.00197413
DP  - 2014 Jul 01
TA  - European Respiratory Journal
PG  - 207--216
VI  - 44
IP  - 1
4099  - http://erj.ersjournals.com/content/44/1/207.short
4100  - http://erj.ersjournals.com/content/44/1/207.full
SO  - Eur Respir J2014 Jul 01; 44
AB  - Obstructive sleep apnoea (OSA) is independently associated with various cardiovascular diseases, including myocardial infarction and stroke. OSA may promote atherosclerosis risk factors such as hypertension, diabetes and dyslipidaemia, and may have direct proatherogenic effects on the vascular wall. A growing number of studies have recently focused on the role of microparticles (MPs) in the atherogenic process. MPs are small plasma membrane vesicles that can be released by a variety of vascular or blood cells, and contain both membrane and cytosolic elements. Case–control studies have shown that platelet-, endothelium- and leukocyte-derived MP levels are increased in OSA. Experimental evidence has demonstrated that MPs from OSA patients induce endothelial dysfunction, inflammation and vascular hyperreactivity when injected into mice. In this review, we provide an overview of the main characteristics of MPs, their expression in OSA and their potential role in the atherogenic process associated with OSA. Overview of microparticles, and their expression in OSA and potential role in the atherogenic process in OSA http://ow.ly/toiAV